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Preincubationa b s t r a c t
While equilibrium binding affinities and in vitro functional antagonism of CB1 receptor antagonists have
been studied in detail, little is known on the kinetics of their receptor interaction. In this study, we there-
fore conducted kinetic assays for nine 1-(4,5-diarylthiophene-2-carbonyl)-4-phenylpiperidine-4-carboxa
mide derivatives and included the CB1 antagonist rimonabant as a comparison. For this we newly devel-
oped a dual-point competition association assay with [3H]CP55940 as the radioligand. This assay yielded
Kinetic Rate Index (KRI) values from which structure-kinetics relationships (SKR) of hCB1 receptor antag-
onists could be established. The fast dissociating antagonist 6 had a similar receptor residence time (RT)
as rimonabant, i.e. 19 and 14 min, respectively, while the slowest dissociating antagonist (9) had a very
long RT of 2222 min, i.e. pseudo-irreversible dissociation kinetics. In functional assays, 9 displayed insur-
mountable antagonism, while the effects of the shortest RT antagonist 6 and rimonabant were surmount-
able. Taken together, this study shows that hCB1 receptor antagonists can have very divergent RTs, which
are not correlated to their equilibrium affinities. Furthermore, their RTs appear to define their mode of
functional antagonism, i.e. surmountable vs. insurmountable. Finally, based on the recently resolved
hCB1 receptor crystal structure, we propose that the differences in RT can be explained by a different
binding mode of antagonist 9 from short RT antagonists that is able to displace unfavorable water mole-
cules. Taken together, these findings are of importance for future design and evaluation of potent and safe
hCB1 receptor antagonists.
 2017 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The human cannabinoid 1 (hCB1) receptor is categorized as a
‘‘lipid G protein-coupled receptor (GPCR)” due to its hydrophobic
endogenous ligands, such as anandamide (AEA) and
L. Xia et al. / Biochemical Pharmacology 151 (2018) 166–179 1672-arachidonoylglycerol (2-AG), which are crucial components of
the endocannabinoid system (ECS) [1,2]. The hCB1 receptor
belongs to the class A GPCR family, and has been shown to signal
through inhibitory Gai/o heterotrimeric G proteins [3], and to inter-
act with b-arrestin [4]. Nowadays, it is widely acknowledged that
the hCB1 receptor is not only present in the central nervous system
(CNS), but also widely distributed in the peripheral nervous system
(PNS) and peripheral tissues [5], including the heart, lung, liver,
gastrointestinal tract, pancreas and adipose tissue [6,7]. The ECS,
including the hCB1 receptor, has been shown to be overactive in
metabolic disorders where increased endocannabinoid levels are
found in plasma, in central and peripheral tissues [8]. Therefore,
blockade of the hCB1 receptor is seen as a potential approach for
the treatment of metabolic disorders such as obese dyslipidemia,
liver disease and diabetes [9].
Rimonabant, as an anti-obesity drug, was the first hCB1 recep-
tor antagonist to reach the market in Europe, but was withdrawn
in 2008 by the manufacturer because of the risk of serious psychi-
atric adverse effects, such as depression [10–13]. As a result, many
research programs in this field were terminated. Afterwards, the
development of peripherally-restricted hCB1 antagonists gained
attention, as they may not have CNS-related side-effects. The gen-
eral strategy was to introduce more polar or even ionic functional
groups to a ligand’s scaffold. However, some recent clinical and
pre-clinical reports on this type of compounds either show no
antiobesity effect at all [14] or no improved effect in comparison
to rimonabant [14–17].
Most recently, the concept of drug target binding kinetics is
receiving increased attention. In particular the receptor-ligand res-
idence time (RT) is emerging as an additional parameter to assess
the therapeutic potential of drug candidates with respect to drug
efficacy and safety [18–20]. The strategic combination of
structure-kinetic relationship (SKR) with classic structure-affinity
relationship (SAR) analyses results in a better understanding of a
ligand-receptor interaction, as together this not only comprises
the equilibrium state of a ligand-receptor interaction but also its
metastable intermediates and/or transition states. Recently, a
number of structure-kinetic relationship (SKR) studies have been
published in the field of GPCRs [21–24]. These suggest that includ-
ing binding kinetic data when triaging compounds can change, and
hopefully improve, the resulting decision process as a compound’s
target affinity and residence time are not always correlated.
In the current study, a series of 9 previously reported
peripherally-selective 1-(4,5-diarylthiophene-2-carbonyl)-4-
phenylpiperidine-4-carboxamide derivatives were selected for a
structure-kinetics relationships (SKR) study, next to structure-
affinity relationships (SAR). These compounds arose from so-
called scaffold hopping, where the pyrazole ring of rimonabant
was replaced by a five-membered thiophene ring [25,26]. In addi-
tion, some polar substituents were introduced on the thiophene
and phenyl rings, as well as a carboxamide moiety; all to increase
the ligands’ polar surface area, and thus to reduce brain penetra-
tion (Table 1). Together with rimonabant as a reference, they were
evaluated in equilibrium and kinetic radioligand binding assays
yielding affinity values and kinetic binding parameters, which
resulted in traditional SAR and novel SKR, respectively. All com-
pounds had high affinities, but possessed diverse kinetic profiles
at the hCB1 receptor. This ‘‘kinetic screening campaign” led to
the identification of a very long (9, 2222 min) and short RT hCB1
receptor antagonist (6, 19 min), while rimonabant was determined
to have a RT of 14 min. Subsequently, we applied two other
radioligand binding experiments (i.e. ‘‘two-step incubation” and
‘‘wash-out” equilibrium displacement experiments) to character-
ize the pseudo-irreversible binding kinetics of antagonist 9, com-
pared to the reversible binding kinetics of antagonist 6 and
rimonabant. With such large differences in RT (185 fold), wedecided to further investigate their concomitant functional effects
in both G protein-dependent and independent (i.e. b-arrestin
recruitment) signaling. Their putative binding mode was analyzed
using the recently resolved crystal structures of the hCB1 receptor
[27], shedding light on key structural features of the receptor bind-
ing site that are involved in dissociation or pseudo-irreversible
binding. In summary, we provide evidence that, next to affinity,
additional knowledge of a compound’s binding kinetics is useful
for selecting and developing new and, potentially, improved
hCB1 receptor antagonists in the early phases of drug discovery.
2. Methods
2.1. Chemicals and reagents
The syntheses of antagonists 1–9 have been described previ-
ously [25,26]. All compounds were fully characterized by HPLC
and 1H NMR. For compounds 1, 2, 3, 4, 8 and 9, purity was analyzed
by a Symmetry C18 column (50  2.1 mm; 3.5 mm), with a 15 min
gradient of acetonitrile/water (0%? 90% CH3CN). For compound 5,
purity was analyzed by an XTerra MS C18 column (50  2.1 mm;
3.5 mm), with a 15 min gradient of acetonitrile/10 mM ammonium
acetate with 3% CH3CN (0%? 90% CH3CN). For compounds 6 and 7,
purity was analyzed by an Acquity BEH C18 column (50  2.1 mm;
1.7 mm), with a 3 min gradient of acetonitrile/water with 3% CH3CN
(1%? 95% CH3CN). All antagonists were found to have a purity of
95% or higher. The compound characterization details for the nine
antagonists are shown below.
2.1.1. 1-[[5-(2,4-Dichlorophenyl)-4-[4-(2-hydroxyethoxy)phenyl]-2-
thienyl]carbonyl]-4-phenyl-4-piperidinecarboxamide (1)
1H NMR (600 MHz, DMSO d6) d 7.72 (s, 1H), 7.59 (s, 1H), 7.48 (s,
2H), 7.43 (d, J = 7.6 Hz, 2H), 7.35 (t, J = 7.7 Hz, 2H), 7.28–7.22 (m,
2H), 7.14–7.08 (m, 3H), 6.85 (d, J = 8.8 Hz, 2H), 4.83 (t, J = 5.5 Hz,
1H), 4.15 (d, J = 12.5 Hz, 2H), 3.94 (t, J = 4.9 Hz, 2H), 3.68 (q, J =
5.2 Hz, 2H), 2.54 (d, J = 8.7 Hz, 2H), 1.89 (t, J = 10.7 Hz, 2H). Purity:
99%. Retention Time: 9.26 min.
2.1.2. 1-[[4-[4-[(2-Aminoethyl)thio]phenyl]-5-(2,4-dichlorophenyl)-2-
thienyl]carbonyl]-4-phenyl-4-piperidinecarboxamide (2)
1H NMR (600 MHz, DMSO d6) d 7.88 (bs, 3H), 7.75 (d, J = 1.8 Hz,
1H), 7.64 (s, 1H), 7.54–7.48 (m, 2H), 7.42 (d, J = 7.4 Hz, 2H), 7.36 (t,
J = 7.8 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 7.25 (t, J = 7.3 Hz, 2H), 7.19
(d, J = 8.4 Hz, 2H), 7.11 (s, 1H), 4.15 (d, J = 11.2 Hz, 2H), 3.17 (t, J
= 7.3 Hz, 2H), 2.95 (t, J = 7.3 Hz, 2H), 2.55 (d, J = 14.1 Hz, 2H),




1H NMR (600 MHz, DMSO d6) d 7.74 (d, J = 1.3 Hz, 1H), 7.65 (s,
1H), 7.54–7.47 (m, 2H), 7.43 (d, J = 7.4 Hz, 2H), 7.35 (t, J = 7.8 Hz,
2H), 7.27 (s, 1H), 7.25 (d, J = 4.5 Hz, 4H), 7.16 (d, J = 8.5 Hz, 2H),
7.10 (s, 1H), 4.16 (d, J = 12.6 Hz, 2H), 3.15–3.10 (m, 2H), 3.10–
3.03 (m, 2H), 2.89 (s, 3H), 2.55 (d, J = 13.5 Hz, 2H), 1.89 (t, J =
10.6 Hz, 2H). Purity: 100%. Retention Time: 9.79 min.
2.1.4. 1-[[5-(2,4-Dichlorophenyl)-4-[4-[3-(methylsulfonyl)propoxy]
phenyl]-2-thienyl]carbonyl]-4-phenyl-4-piperidinecarboxamide (4)
1H NMR (600 MHz, DMSO d6) d 7.73 (s, 1H), 7.60 (s, 1H), 7.48 (d,
J = 1.0 Hz, 2H), 7.42 (d, J = 7.4 Hz, 2H), 7.35 (t, J = 7.8 Hz, 2H), 7.28–
7.22 (m, 2H), 7.13 (d, J = 8.8 Hz, 2H), 7.10 (s, 1H), 6.86 (d, J = 8.8 Hz,
2H), 4.16 (d, J = 14.0 Hz, 2H), 4.05 (t, J = 6.2 Hz, 2H), 3.26–3.22 (m,
2H), 3.00 (sz, 3H), 2.55 (d, J = 13.6 Hz, 2H), 2.16–2.07 (m, 2H), 1.89
(t, J = 11.2 Hz, 2H). Purity: 95%. Retention Time: 9.64 min.
Table 1
Equilibrium binding affinity (Ki) and kinetic parameters (KRI, kon, koff, RT and KD) for hCB1 receptor antagonists.


















14 ± 2.0 5.9 ± 0.3 N.D.i
1 –OCH2CH2OH 9.3 ± 0.1 (0.53) 0.81 ± 0.02 N.D. N.D. N.D. N.D. 7.7 ± 0.1 (22)
2 –SCH2CH2NH2 9.3 ± 0.04 (0.53) 1.30 ± 0.21 N.D. N.D. N.D. N.D. 7.8 ± 0.5 (33)




556 ± 124 0.22 ± 0.07 8.8 ± 0.04 (1.6)
4 –OCH2CH2CH2SO2CH3 9.3 ± 0.1 (0.50) 1.08 (1.10; 1.06) N.D. N.D. N.D. N.D. 7.3 ± 0.1 (58)
5 –SCH2CH2CH2OH 9.6 ± 0.1 (0.28) 1.02 ± 0.31 N.D. N.D. N.D. N.D. 8.2 ± 0.3 (9.7)




19 ± 3.6 18 ± 3.1 7.2 ± 0.1 (74)




357 ± 51 0.34 ± 0.02 7.6 ± 0.1 (26)




435 ± 132 0.19 ± 0.05 7.4 ± 0.02 (38)




2222 ± 888 0.084 ± 0.026 7.3 ± 0.1 (54)
a pKi ± SEM (n = 3), obtained from radioligand binding assays with [3H] CP55940 on recombinant human CB1 receptors stably expressed on CHO cell membranes.
b KRI ± SEM (n = 3) or KRI (n1; n2) (n = 2), obtained from dual-point competition association assays with [3H] CP55940 on recombinant human CB1 receptors stably
expressed on CHO cell membranes.
c kon ± SEM (n = 3), obtained from competition association assays with [3H] CP55940 on recombinant human CB1 receptors stably expressed on CHO cell membranes.
d koff ± SEM (n = 3), obtained from competition association assays with [3H] CP55940 on recombinant human CB1 receptors stably expressed on CHO cell membranes.
e RT = 1/(60 * koff); RT is expressed in min, whereas koff is expressed in s-1.
f KD = koff/kon.
g pKi ± SEM (n = 3), obtained from radioligand binding assays with [3H] CP55940 on recombinant human CB2 receptors stably expressed on CHO cell membranes.
h N.A. not applicable.
i N.D. not determined.
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phenyl]-2-thienyl]carbonyl]-4-phenyl-4-piperidinecarboxamide (5)
1H NMR (600 MHz, DMSO d6) d 7.73 (d, J = 0.9 Hz, 1H), 7.63 (s,
1H), 7.49 (d, J = 1.7 Hz, 2H), 7.42 (d, J = 7.4 Hz, 2H), 7.36 (t, J = 7.8
Hz, 2H), 7.25 (t, J = 7.2 Hz, 2H), 7.21 (d, J = 8.5 Hz, 2H), 7.14 (d, J
= 8.5 Hz, 2H), 7.10 (s, 1H), 4.55 (t, J = 5.2 Hz, 1H), 4.15 (d, J = 13.4
Hz, 2H), 3.47 (q, J = 6.0 Hz, 2H), 2.98 (t, J = 7.3 Hz, 2H), 2.57–2.52
(m, 2H), 1.89 (t, J = 12.4 Hz, 2H), 1.69 (p, J = 6.6 Hz, 2H). Purity:
100%. Retention Time: 9.28 min.2.1.6. 1-[[5-(2,4-Dichlorophenyl)-4-[4-[(3-hydroxypropyl)sulfonyl]
phenyl]-2-thienyl]carbonyl]-4-phenyl-4-piperidinecarboxamide (6)
1H NMR (600 MHz, DMSO d6) d 7.81 (d, J = 8.4 Hz, 2H), 7.76–
7.73 (m, 2H), 7.55 (d, J = 8.3 Hz, 1H), 7.52 (dd, J = 8.3, 2.0 Hz, 1H),
7.48 (d, J = 8.5 Hz, 2H), 7.43 (d, J = 7.5 Hz, 2H), 7.36 (t, J = 7.8 Hz,
2H), 7.25 (t, J = 7.2 Hz, 2H), 7.10 (s, 1H), 4.63 (t, J = 5.3 Hz, 1H),
4.17 (d, J = 13.3 Hz, 2H), 3.40 (q, J = 6.0 Hz, 2H), 3.30–3.24 (m,
2H), 2.54 (d, J = 14.2 Hz, 2H), 1.90 (t, J = 12.3 Hz, 2H), 1.70–1.60
(m, 2H). Purity: 100%. Retention Time: 1.52 min.2.1.7. 1-[[5-(2,4-Dichlorophenyl)-4-[4-[(4-hydroxybutyl)thio]phenyl]-
2-thienyl]carbonyl]-4-phenyl-4-piperidinecarboxamide (7)
1H NMR (600 MHz, DMSO d6) d 7.73 (d, J = 0.8 Hz, 1H), 7.64 (s,
1H), 7.52–7.47 (m, 2H), 7.43 (d, J = 7.5 Hz, 2H), 7.36 (t, J = 7.8 Hz,2H), 7.26 (t, J = 7.2 Hz, 2H), 7.21 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 8.4
Hz, 2H), 7.11 (s, 1H), 4.42 (t, J = 5.1 Hz, 1H), 4.16 (d, J = 13.3 Hz,
2H), 2.95 (t, J = 7.2 Hz, 2H), 2.54 (d, J = 15.6 Hz, 2H), 1.90 (t, J =
12.6 Hz, 2H), 1.63–1.56 (m, 2H), 1.55–1.49 (m, 2H). Purity: 100%.
Retention Time: 1.79 min.2.1.8. 4-[5-[(4-Carbamoyl-4-phenylpiperidin-1-yl)carbonyl]-2-(2,4-
dichlorophenyl)thien-3-yl]phenyl propane-1-sulfonate (8)
1H NMR (600 MHz, DMSO d6) d 7.74 (d, J = 2.0 Hz, 1H), 7.68 (s,
1H), 7.51 (dt, J = 8.3, 5.2 Hz, 2H), 7.43 (d, J = 7.4 Hz, 2H), 7.36 (t, J
= 7.8 Hz, 2H), 7.33–7.29 (m, 2H), 7.29–7.23 (m, 4H), 7.11 (s, 1H),
4.16 (d, J = 13.3 Hz, 2H), 3.56–3.46 (m, 2H), 2.54 (d, J = 14.0 Hz,
2H), 1.90 (t, J = 12.2 Hz, 2H), 1.86–1.78 (m, 2H), 1.02 (t, J = 7.4 Hz,
3H). Purity: 98%. Retention Time: 10.62 min.2.1.9. 1-[[5-(2,4-Dichlorophenyl)-4-[4-[3-(methylthio)propoxy]
phenyl]-2-thienyl]carbonyl]-4-phenyl-4-piperidinecarboxamide (9)
1H NMR (600 MHz, DMSO d6) d 7.72 (s, 1H), 7.59 (s, 1H), 7.48 (d,
J = 1.0 Hz, 2H), 7.43 (d, J = 7.4 Hz, 2H), 7.36 (t, J = 7.8 Hz, 2H), 7.25
(t, J = 7.2 Hz, 2H), 7.17–7.07 (m, 3H), 6.85 (d, J = 8.8 Hz, 2H), 4.15
(d, J = 12.2 Hz, 2H), 4.01 (t, J = 6.1 Hz, 2H), 2.59 (t, J = 7.2 Hz, 2H),
2.54 (d, J = 13.1 Hz, 2H), 2.05 (s, 3H), 1.97–1.91 (m, 2H), 1.91–
1.83 (m, 2H). Purity: 98%. Retention Time: 11.43 min.
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(specific activity 1250 Ci/mmol) were purchased from Perkin
Elmer (Waltham, MA). Bicinchoninic acid (BCA) and BCA protein
assay reagent were obtained from Pierce Chemical Company
(Rochford, IL). Rimonabant (SR141716A) was from Cayman
Chemical Company (Ann Arbor, MI). CHOK1hCB1_bgal and
CHOK1hCB2_bgal cells (catalog number 93-0959C2 and 93-
0706C2) and the Pathhunter detection kit (catalog number 93–
0001M) were obtained from DiscoveRx (Fremont, CA). All other
chemicals were of analytical grade and obtained from standard
commercial sources.
2.2. Cell culture and membrane preparation
CHOK1hCB1_bgal cells and CHOK1hCB2_bgal cells were cul-
tured in Ham’s F12 Nutrient Mixture supplemented with 10% fetal
calf serum (FCS), 1 mM glutamine, 50 lg/ml penicillin, 50 lg/ml
streptomycin, 300 mg/ml hygromycin and 800 lg/ml geneticin in
a humidified atmosphere at 37 C and 5% CO2. Cells were subcul-
tured twice a week at a ratio of 1:10 on 10-cm ø plates by
trypsinization. For membrane preparation the cells were subcul-
tured 1:10 and transferred to large 15 cm ø plates. Membrane
fractions were prepared as described before [28].
2.3. Radioligand equilibrium displacement assays
Membrane aliquots containing 5 lg (CHOK1hCB1_bgal) or 1.5
lg (CHOK1hCB2_bgal) protein were incubated in a total volume
of 100 ll assay buffer (50 mM Tris–HCl, 5 mM MgCl2, 0.1% BSA,
pH 7.4) at 30 C for 60 min. Displacement experiments were per-
formed using 6 concentrations of competing antagonist in the
presence of a final concentration of 3 nM [3H]CP55940
(CHOK1hCB1_bgal) or 1.5 nM [3H]CP55940 (CHOK1hCB2_bgal).
At this concentration, total radioligand binding did not exceed
10% of that added to prevent ligand depletion. Nonspecific binding
(NSB) was determined in the presence of 10 lM rimonabant
(CHOK1hCB1_bgal) or 10 lM AM630 (CHOK1hCB2_bgal). For the
‘‘two-step incubation” assays, antagonists were first pre-
incubated with membrane aliquots at 30 C for 3 h, then 3 nM
of [3H]CP55940 was added and coincubated for a further 60 min.
For all experiments, incubation was terminated by rapid filtration
performed on 96-well GF/C filter plates (Perkin Elmer, Groningen,
the Netherlands), presoaked for 30 min with 0.25% PEI (Polyethyle-
neImine), using a PerkinElmer Filtermate-harvester (Perkin Elmer,
Groningen, the Netherlands). After drying the filter plate at 50 C
for 30 min, the filter-bound radioactivity was determined by scin-
tillation spectrometry using the 2450 MicroBeta2 Plate Counter
(Perkin Elmer, Boston, MA).
2.4. ‘‘Wash-out” assays
For washout experiments, 100 ll assay buffer containing either
1% DMSO (as blank control for total binding and non-specific bind-
ing) or antagonist (9, 6 or rimonabant, final concentration 1 lM
stock in assay buffer) was added to 1.5-ml Eppendorf tubes con-
taining 20 lg of CHOK1hCB1_bgal protein. This mixture was
brought to a total volume of 300 ll assay buffer, which was then
incubated at 30 C for 1 h. Subsequently, the mixture was cen-
trifuged at 13,000 revolutions per minute (RPM) at 4 C for 5 min
to allow the removal of the supernatant containing unbound
ligand. Then the membrane pellet was resuspended in 1 ml assay
buffer by vortexing and spun at 13,000 RPM at 4 C for 10 min.
After three washing cycles, the membrane pellets were resus-
pended in 300 ll assay buffer and placed on ice. Subsequently,
100 ll [3H] CP55940 (3 nM) was added, followed by another
incubation at 30 C for 60 min. Incubation was terminated by rapidfiltration performed on GF/C filters (Whatman International, Maid-
stone, UK), presoaked for 30 min with 0.25% PEI, using a Brandel
harvester (Brandel, Gaithersburg, MD). Filter-bound radioactivity
was determined by scintillation spectrometry using a Tri-Carb
2900 TR liquid scintillation counter (Perkin Elmer, Boston, MA).
2.5. Radioligand association and dissociation assays
Association experiments were performed by incubating mem-
brane aliquots containing 5 lg of CHOK1hCB1_bgal membrane in
a total volume of 100 ll of assay buffer at 30 C with 3 nM [3H]
CP55940. The amount of radioligand bound to the receptor was
measured at different time intervals during a total incubation of
120 min. Dissociation experiments were performed by preincubat-
ing membrane aliquots containing 5 lg of protein in a total volume
of 100 ll of assay buffer for 60 min. After the preincubation, radi-
oligand dissociation was initiated by the addition of 5 ll 10 lM
unlabeled rimonabant. The amount of radioligand still bound to
the receptor was measured at various time intervals for a total of
240 min to ensure that full dissociation from hCB1 receptor was
reached. Incubations were terminated and samples were obtained
as described under Methods 2.4.
2.6. Radioligand competition association assays
The binding kinetics of unlabeled ligands were quantified using
the competition association assay based on the theoretical frame-
work by Motulsky and Mahan [29]. The competition association
assay was initiated by adding membrane aliquots (5 lg/well) at
different time points for a total of 240 min to a total volume of
100 ll of assay buffer at 30 C with 3 nM [3H]CP55940 in the
absence or presence of a single concentration of competing hCB1
receptor antagonists (1–3-fold IC50). Incubations were terminated
and samples were obtained as described under Methods 2.3. The
‘‘dual-point” competition association assays were designed as
described previously [30], where in this case the two time points
were selected at 30 (t1) and 240 min (t2).
2.7. [35S]GTPcS binding assays for selected long and short RT
antagonists (9, 6, rimonabant)
The assays were performed by incubating 5 mg of homogenized
CHOK1CB1_bgal membranes in a total volume of 80 ml assay buffer
(50 mM Tris-HCl buffer, 5 mM MgCl2, 150 mM NaCl, 1 mM EDTA,
0.05% BSA and 1 mM DTT, pH 7.4) supplemented with 1 mM GDP
and 5 mg saponin. The assays were performed in a 96-well plate
format, where DMSO stock solutions of the compounds were added
using a HP D300 Digital Dispenser (Tecan, Männedorf, Switzer-
land). The final concentration of organic solvent per assay point
was 0.1%. In all cases, the basal level of [35S]GTPcS binding was
measured in untreated membrane samples, whereas the maximal
level of [35S]GTPcS binding was measured by treatment of the
membranes with 1 lM CP55940, unless stated otherwise. To
determine the IC50 values (inverse agonism) of hCB1 receptor
antagonists, as well as EC50 values of CP55940 (a reference CB1
receptor agonist), the membranes were incubated with increasing
concentrations of ligand for 90 min at 30 C. To determine the IC50
(antagonism) values of hCB1 receptor antagonists, membrane
preparations were pre-incubated for 30 min at 30 C with a range
of concentrations of the antagonists prior to the addition of an
EC80 concentration of CP55940 (3.8 nM) and 20 ml [35S]GTPcS (final
concentration 0.3 nM) after which incubation continued for
another 90 min at 30 C. For the insurmountability experiments,
membrane preparations were pre-incubated with or without
antagonists (10-, 30-, 100-fold Ki values) for 60 min at 30 C, prior
to the addition of CP55940 (1 mM to 0.1 nM) and 20 ml [35S]GTPcS
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for another 30 min at 30 C. For the surmountability (control)
experiments, antagonists and CP55940 were co-incubated with
[35S]GTPcS for 30 min at 30 C. For all experiments, incubations
were terminated and samples were obtained as described under
Methods 2.3, by using GF/B filters (Whatman International, Maid-
stone, UK).
2.8. PathHunter b-arrestin recruitment assays for selected long and
short RT antagonists (9, 6, rimonabant)
The PathHunter protein complementation assay (Fremont, CA,
USA) was performed according to the manufacturer’s protocol [31].
CHOK1hCB1_bgal cells were seeded at a density of 5000 cells per
well of solid black-walled 384-well plates (Catalog number 3712,
Corning, NY, USA) in 20 ll cell culture medium and incubated
overnight in a humidified atmosphere at 37 C and 5% CO2. DMSO
stock solutions of the compounds were added using a HP D300
Digital Dispenser (Tecan, Männedorf, Switzerland). The final con-
centration of organic solvent per assay point was 0.1%. The basal
level of b-arrestin recruitment was measured in untreated cells,
and the maximal level of b-arrestin recruitment was measured
by treatment of cells with 1 lM CP55940, unless stated otherwise.
To determine the IC50 values (inverse agonism) of hCB1 receptor
antagonists, as well as EC50 values of CP55940, the cells were stim-
ulated with increasing concentrations of ligand and incubated for
90 min (standard duration) or 6 h (extended duration) in a humid-
ified atmosphere at 37 C and 5% CO2. To determine the IC50 (inhi-
bition) values of hCB1 receptor antagonists, the cells were exposed
to increasing concentrations of each antagonist and preincubated
for 30 min under the same condition, followed by the addition of
an EC80 concentration of CP55940 (39 nM), after which the cells
were incubated for 90 min in a humidified atmosphere at 37 C
and 5% CO2. For the insurmountability assays, the cells were pre-
incubated with or without antagonists (10-, 30-, 100-fold Ki values
on the hCB1 receptor) for 60 min, after that CP55940 (1 mM to 0.1
nM) was added and incubated for another 30 min. For the sur-
mountability (control) experiments, antagonists and CP55940
were co-incubated for 30 min at 37 C and 5% CO2. For all the
experiments, b-galactosidase enzyme activity was determined by
using the PathHunter detection mixture, according to the kit’s
protocol [31]. Detection mixture (12 ll per well) was added and
the plate was incubated for 60 min in the dark at room tempera-
ture. Chemiluminescence, indicated as relative light units (RLU),
was measured on an EnVision multilabel plate reader (Perkin
Elmer, MA, USA).
2.9. Computational studies on selected long and short RT antagonists
(9, 6, rimonabant)
The computational studies were based on the crystal structure
of the hCB1 receptor co-crystalized with AM6538 (PDB: 5TGZ)
[27] and prepared with the protein preparation wizard [32]. Since
the antagonists 9, 6 and rimonabant were similar to the co-
crystalized AM6538, induced fit docking [33] was used with core
constraints on the 2,4-dichlorophenyl ring of AM6538. To study
to the potential differences in hydration between ligands, an apo
(without ligand present) WaterMap was generated [34,35]. Figures
were rendered using PyMol [36], for clarity the ‘‘cartoon” represen-
tation of residues 362–375 was hidden.
2.10. Data analysis
All experimental data were analyzed using the nonlinear regres-
sion curve fitting programGraphPad Prism 6.0 (GraphPad Software,
Inc., San Diego, CA). From displacement assays, IC50 values wereobtained by non-linear regression analysis of the displacement
curves. The obtained IC50 valueswere converted into Ki values using
the Cheng-Prusoff equation to determine the affinity of the ligands
[37], using KD values of 0.10 nM (CHOK1hCB1_bgal) and 0.33 nM
(CHOK1hCB2_bgal) [38]. The observed association rates (kobs)
derived from both assays were obtained by fitting association data
using ‘one phase exponential association’. The dissociation rate con-
stants were obtained by fitting dissociation data to a ‘one phase
exponential decay’ model. The kobs valueswere converted into asso-
ciation rate constants (kon) using the equation kon = (kobs  koff)/[L],
where [L] is the amount of radioligand used for the association
experiments. The association and dissociation rate constants were
used to calculate the kinetic KD using the equation KD = koff/kon.
The residence time (RT, in min) was calculated using the equation
RT = 1/(60 * koff), as koff is in s1. Association and dissociation rate
constants for unlabeled compounds were calculated by fitting the
data into the competition associationmodel using ‘‘kinetics of com-
petitive binding” [29]:
KA ¼ k1½L  109 þ k2
KB ¼ k3½I  109 þ k4
S ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðKA  KBÞ2 þ 4  k1  k3  L  I  1018
q
KF ¼ 0:5ðKA þ KB þ SÞ
KS ¼ 0:5ðKA þ KB  SÞ
Q ¼ Bmax k1 L109KFKS
Y ¼ Q  k4 ðKFKSÞKF KS þ
k4KF
KF
eðKF XÞ  k4KSKS eðKS XÞ
 
where k1 is the kon of the radioligand (M1 s1), k2 is the koff of the
radioligand (s1), L is the radioligand concentration (nM), I is the
concentration of the unlabeled competitor (nM),  is the time (s)
and Y is the specific binding of the radioligand (DPM). The control
curve (without competitor) from competition association assays
generated the k1 value, and the k2 value was obtained in previous
experiments (data not shown). With that the k3, k4 and Bmax were
calculated, where k3 represents the kon (M1 s1) of the unlabeled
ligand, k4 stands for the koff (s1) of the unlabeled ligand and Bmax
equals the total binding (DPM). All competition association data
were globally fitted. [35S]GTPcS binding and b-arrestin recruitment
curves were analyzed by nonlinear regression using ‘‘log (agonist or
inhibitor) vs. response-variable slope” to obtain potency, inhibitory
potency or efficacy values of agonists and inverse agonists (EC50,
IC50 or Emax, respectively). In the (in)surmountability assays, the
Gaddum/Schild EC50 shift equations were used to obtain the
Schild-slopes and pA2 values; statistical analysis of two-way
ANOVA with Tukey’s post-test was applied. All values obtained
are means of at least three independent experiments performed
in duplicate, unless stated otherwise.3. Results
3.1. Binding affinity (Ki) of hCB1 receptor antagonists
The binding affinities of nine hCB1 receptor antagonists were
determined in equilibrium radioligand displacement studies. All
antagonists were able to concentration-dependently inhibit speci-
fic [3H]CP55940 binding to the human CB1 receptor and their
affinities are listed in Table 1. All antagonists had a high binding
affinity, ranging from 0.13 nM for antagonist 8 to 14 nM for antag-
onist 6, while the reference antagonist, rimonabant, had an affinity
of 1.8 nM. Moreover, we determined the affinity of all nine com-
pounds on the hCB2 receptor. From Table 1 it follows that they
all had higher affinity for the hCB1 receptor, where approximately
5- to 292-fold selectivity over hCB2 receptors was observed.
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Subsequently, these hCB1 receptor antagonists were screened
in the so-called ‘‘dual-point” competition association assay. The
specific binding of [3H]CP55940 was measured after 30 and 240
min in the absence and presence of a single concentration of unla-
beled hCB1 receptor antagonists, which yielded their Kinetic Rate
Index (KRI). The KRI values of the hCB1 receptor antagonists ran-
ged from 0.65 to 1.57 (Table 1). Antagonists with a KRI value
>1.0 were considered to have a slower dissociation rate, and thus
a longer RT, than the radioligand used, i.e. [3H]CP55940, and vice
versa. Four antagonists (3, 7, 8 and 9) had KRI values 1.3, whereas
two antagonists (6 and rimonabant) had KRI values 0.7 (Table 1).3.3. Structure-affinity relationships (SAR) and structure-kinetics
relationships (SKR) of hCB1 receptor antagonists
The obtained affinities (Ki values) and kinetic profiles (kon, koff
values and RTs) permitted us to derive SAR and SKR for this series
of antagonists. Different sidechains were examined as the R group
(Table 1). On antagonist 1 the R1 substituent was a 2-
hydroxyethoxy, which resulted in a high affinity of 0.53 nM and
a KRI-value of 0.81. When the side chain of antagonist 1 was
replaced by a similar 2-mercaptoethylamine (2), its affinity was
unchanged and its KRI value was substantially increased to 1.30.
When the terminal amine of 2 was extended by methanesulfonyl
(–SO2CH3) as in antagonist 3, it yielded an approximately 3-fold
increased affinity (0.53 nM vs. 0.19 nM) and slightly higher KRI
value (1.39). The slightly less polar side chain of antagonist 4 didFig. 1. Competition association experiments with [3H]CP55940 binding to recombinant
presence of unlabeled long-residence-time antagonist 9 (A), short-residence-time antago
from one experiment performed in duplicate. Note, t1, t2 are indicated, which were thenot improve affinity in comparison to 2 but slightly reduced the
KRI value (1.08). Next, a 3-mercapto-1-propanol side chain was
introduced (5), which did not affect the affinity, but the com-
pound’s KRI value was close to unity (1.02). When the thio-ether
of 5 was oxidized to sulfonyl (6), the affinity was decreased by
50-fold to 14 nM and the KRI value reduced to 0.70. When the pro-
pyl side chain of antagonist 5was extended to a butyl (7), the affin-
ity remained the same (0.28 nM vs. 0.24 nM), but its KRI value
increased to 1.32. Lastly, antagonists 8 and 9 were obtained by
slight variations of the linear side chains from antagonists 6 and
7, respectively, which resulted in pronounced effects on both affin-
ity and kinetics. From the 5-mercapto-1-pentanol side chain (7) to
3-(methylthio)propan-1-ol (9), the affinity dropped by approxi-
mately 6-fold (0.24 nM vs. 1.4 nM), while the KRI value increased
from 1.32 to the highest of the series (1.57). From sulfonic 1-
propanol (6) to alkyl sulfate (8), not only the affinity improved
from 14 nM to 0.13 nM (107-fold), but also its KRI value increased
from the lowest value of the series (0.70) to the second highest
value (1.51, Table 1).3.4. Binding kinetics of selected hCB1 receptor antagonists using the
competition association assay
Next, the kinetic binding parameters of six antagonists that had
either low or high KRI values (3, 6, 7, 8, 9 and rimonabant) were
determined using the competition association assay with [3H]
CP55940. Association rate constants varied by merely 4.5-fold,
ranging from (5.2 ± 0.7)  104 M1 s1 for compound 6 to
(2.3 ± 0.3)  105 M1 s1 for rimonabant (Table 1). There was ahCB1 receptors stably expressed on CHO cell membranes (30 C) in the absence or
nist 6 (A), or reference antagonist rimonabant (B). Representative graphs are shown
two time points used in KRI determinations. Data are summarized in Table 1.
Fig. 2. The correlations between the negative logarithm of the hCB1 receptor antagonists’ dissociation rate constants (pkoff) and their Kinetic Rate Index (KRI) (A), the CB1
receptor antagonists’ affinity (pKi) and their ‘‘kinetic KD” (pKD) (B), association rate constants (log kon) (C) and dissociation rate constants (pkoff) (D). The data point of the
longest RT antagonist 9 is highlighted in red. Data used in these plots are detailed in Table 1. The central line corresponds to the linear regression of the data, the dotted lines
represent the 95% confidence intervals for the regression.
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divergent KRI values. Rimonabant had the fastest dissociation rate
constant of (1.4 ± 0.2)  103 s1 and thus the shortest RT of 14
min, while compound 9 had the slowest dissociation rate constant
of (7.5 ± 3.0)  106 s1 and thus the longest RT of 2222 min
(Table 1). Of note, the long RT antagonist 9 (Fig. 1A) displayed a
typical ‘‘overshoot” in the association curve, indicative of a slower
dissociation than [3H]CP55940, while the short RT antagonists,
both antagonist 6 (Fig. 1A) and rimonabant (Fig. 1B), presented
gradually ascending curves. Notably, a good correlation between
the negative logarithm of the antagonist’s dissociation rate con-
stants and their KRI values derived from the kinetic assays was
obtained (Fig. 2A), which confirmed that a compound’s KRI value
is a good predictor for its dissociation rate constant. A significant
correlation was also observed between the antagonist affinities
(pKi values) determined in equilibrium displacement experiments
and their pKD values derived from competition association experi-
ments (Fig. 2B). In contrast, the kinetic parameters (log kon or pkoff
values) of the hCB1R antagonists did not show a significant corre-
lation with their affinities (Fig. 2C and D).3.5. Binding kinetics of selected hCB1 receptor antagonists using
(pseudo-)equilibrium binding assays
As another means to investigate differences in compound bind-
ing kinetics, ‘‘two-step incubation” equilibrium displacement
experiments were performed for the long (9) and short RTantagonists (6 and rimonabant), as shown in Fig. 3A–C. When the
displacement curves of the longest RT antagonist 9 were compared
with the control and the two-step incubation, a significant one log-
unit shift was observed (Fig. 3A) resulting in a pKi of 8.9 ± 0.1–9.8 ±
0.1, respectively. In contrast, no such affinity-shift was observed
for either short RT antagonist (Fig. 3B and C, Table 2), indicative
of quick equilibration kinetics.
The observed affinity-shift of the long RT antagonist 9 was
further investigated in a ‘‘wash-out” experiment. As shown in
Fig. 3D, once the long RT antagonist 9 saturated hCB1 receptors dur-
ing pre-incubation, they could not be recovered by washing as indi-
cated by a lack of [3H]CP55940 binding, while for both short RT
antagonists (6 and rimonabant) washing of pre-saturated hCB1
receptors did result in significant restoration of [3H]CP55940 bind-
ing. Taken together, these two (pseudo-)equilibrium experiments
yielded a qualitative indication that antagonist 9 had significantly
slower dissociation kinetics from hCB1 receptors than rimonabant
and antagonist 6. This was in agreement with the quantitative
results obtained from the (dual-point) competition association
experiments.3.6. Computational studies on selected long and short RT antagonists
In addition, to study differences between RT and binding
modes, rimonabant, antagonists 6 and 9 were docked using
induced-fit docking. An apo-WaterMap was generated on the basis
that the small cavity, formed by W279543, I280544 and L360652,
Fig. 3. The ‘‘two-step incubation” experiments with [3H]CP55940 binding to
recombinant hCB1 receptors stably expressed on CHO cell membranes (30 C) in
the absence or presence of unlabeled long-residence-time antagonist 9 (A), short-
residence-time antagonist 6 (B), or reference antagonist rimonabant (C). Combined
graphs are shown from three experiments performed in duplicate. The ‘‘wash-out”
experiment with [3H]CP55940 binding to recombinant hCB1 receptors stably
expressed on CHO cell membranes (30 C) in the absence (UTB and TB) or presence
of 1 mM of the longest RT antagonist 9, the short RT antagonist 6 or reference
antagonist rimonabant (D). The percentage of the specific radioligand binding
relative to the unwashed blank control (UTB, 100%) is 83 ± 6.2% for washed blank
control (TB), 3.8 ± 4.1% for antagonist 9, 59 ± 2.2% for antagonist 6 and 44 ± 4.4% for
rimonabant. Data are mean values ± SEM of three independent experiments in
duplicate (see Table 2 for pKi values).
Table 2
Affinities of selected long (9) and short (6) RT hCB1 receptor antagonists determined










9 9.8 ± 0.1* 8.9 ± 0.1 +0.9
6 7.9 ± 0.04ns 7.9 ± 0.01 0
Rimonabant 8.7 ± 0.1ns 8.8 ± 0.1 0.1
Student’s t-test was applied for the comparison of ‘‘affinity” obtained from ‘‘two-
step” incubation by standard affinity, *p < 0.05, ns for not significant.
a pKi ± SEM (n = 3), obtained from radioligand binding assays with [3H] CP55940
on recombinant human CB1 receptors stably expressed on CHO cell membranes.
b pKi ± SEM (n = 3), obtained from radioligand binding assays with [3H] CP55940
on recombinant human CB1 receptors stably expressed on CHO cell membranes
(taken from Table 1 for comparison).
c Affinity shift = pKi (two-step incubation)  pKi (standard assay).
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W72 in Fig. 4).W11 (DG = 8.69 kcal/mol) was one of the most unfa-
vorable hydration centers in this WaterMap. This hydration centeris neither displaced by rimonabant nor by the short RT antagonist 6
(Fig. 4A and C). Interestingly, following from the proposed binding
pose of the long RT antagonist 9, this hydration center can be dis-
placed by this antagonist (Fig. 4B) as the pocket formed by the
aforementioned residues is being opened.3.7. Functional characterization of long and short RT antagonists
Subsequently, the short RT antagonists (6 and rimonabant) and
long RT antagonist (9) were functionally characterized in hCB1
receptor agonist-induced [35S]GTPcS binding and G protein-
independent (b-arrestin recruitment) assays. Firstly, their antago-
nistic behavior was revealed on both G protein-dependent and
independent signaling (Table 3), as all antagonists caused a dose-
dependent decrease in agonist-induced signaling. The long RT
antagonist 9 had the highest antagonistic potency in both [35S]
GTPcS binding and b-arrestin recruitment assays (3.0 nM and 30
nM, respectively), while potencies of the short RT antagonist 6
were the lowest (589 nM and 8261 nM, respectively). Interestingly,
the antagonist potencies were significantly lower in b-arrestin
recruitment compared to [35S]GTPcS binding assays, where the
potencies obtained from the latter were in closer agreement to
the affinity values.
Secondly, their mode of antagonism, i.e. surmountable or insur-
mountable, was investigated in both [35S]GTPcS binding and b-
arrestin recruitment assays. Pretreatment of CHOK1hCB1 receptor
membranes ([35S]GTPcS binding, Fig. 5A) or cells (b-arrestin
recruitment, Fig. 6A) with increasing concentrations of the long
RT antagonist 9 before stimulation by the CB1 receptor agonist
CP55940 induced insurmountable antagonism (Fig. 5A). In other
words, the CP55940 concentration-effect curves were shifted to
the right with a concomitant decrease in the maximal response.
Conversely, the short RT antagonists (6 and rimonabant) displayed
surmountable antagonism, i.e. shifting CP55940’s curves to the
right without affecting its maximum effect ([35S]GTPcS binding,
Fig. 5C, E; and b-arrestin recruitment, Fig. 6C, E). Under such
experimental set-up, the obtained Schild-slopes of both 6 and
rimonabant were close to unity in either [35S]GTPcS binding or
b-arrestin recruitment assays (Table 3). Moreover, from [35S]GTPcS
binding assays the pA2 value of 6 was close to its pKi value
(8.5 ± 0.5 from Table 3 vs. 7.9 ± 0.01 from Table 2), while for
rimonabant these were more divergent (10 ± 0.2 from Table 3 vs.
8.8 ± 0.1 from Table 2). In addition, pA2 values derived from
b-arrestin recruitment assays for 6 and rimonabant were less
comparable with the corresponding pKi values. Next, we per-
formed co-incubation experiments with these antagonists in the
presence of CP55940 ([35S]GTPcS binding, Fig. 5B, D, F; and b-
arrestin recruitment, Fig. 6B, D, F). In this experimental set-up,
Fig. 4. Docking of rimonabant (A), antagonist 9 (B) and antagonist 6 (C) into the binding site of the crystal structure of the hCB1 receptor (PDB: 5TGZ) [27] co-crystalized with
AM6538 (not shown), showing the overlay of numbered consecutively hydration sites of the apo-WaterMap. Hydration sites shown as red spheres represent ‘‘unstable” water
molecules (>5 kcal/mol), whereas white spheres symbolize ‘‘stable” water molecules. For the unfavorable hydration centers (‘‘unstable” water molecules) the DG is reported
(A). Rimonabant is represented by black sticks, and residues within 5 Å of rimonabant are visualized as blue sticks. The protein is represented by blue ribbons (A). Antagonist
9 is represented by black sticks, and residues within 5 Å of 9 are visualized as green sticks. The protein is represented by green ribbons. The displaced unstable water molecule
was covered with a cross (B). Antagonist 6 is represented by black sticks, and residues within 5 Å of 6 are visualized as yellow sticks. The displaced unstable water molecule
was covered with a cross (C). The protein is represented by yellow ribbons. Ligand and residue atoms’ color code: yellow = sulfur, red = oxygen, blue = nitrogen, white =
hydrogen.
Table 3
Functional effects of selected long (9) and short (6) RT hCB1 receptor antagonists determined by [35S]GTPcS binding and b-arrestin recruitment assays, using rimonabant as a
reference.




Antagonist pIC50 ± SEM
(IC50 in nM) a
pA2b The Schild slopeb pA2b The Schild slopeb pIC50 ± SEM
(IC50 in nM)c
9 8.5 ± 0.0
(3.0)
N.A.d N.A. 8.9 ± 0.0 2.4 ± 0.2 8.6 ± 0.1
(2.7)
6 6.3 ± 0.1
(589)
8.5 ± 0.5 1.0 ± 0.2 9.1 ± 0.2 1.1 ± 0.0 7.1 ± 0.1
(84)
Rimonabant 8.0 ± 0.1
(11)




9 7.5 ± 0.0
(30)
N.A. N.A. 8.1 ± 0.1 1.8 ± 0.0 6.8 ± 0.2
(165)
6 5.1 ± 0.0 (8261) 6.4 ± 0.0 1.2 ± 0.2 7.7 ± 0.1 0.7 ± 0.2 6.8 ± 0.2
(179)
Rimonabant 6.8 ± 0.1 (184) 8.0 ± 0.2 1.3 ± 0.3 8.2 ± 0.4 1.2 ± 0.3 6.3 ± 0.2
(627)
a pIC50 ± SEM, obtained from either [35S]GTPcS binding (n = 4) or b-arrestin recruitment (n = 3) assays on recombinant human CB1 receptors stably expressed on CHO cell
membranes or intact cell line.
b Obtained from the Schild analyses, [35S]GTPcS binding assays (n = 3) or b-arrestin recruitment assays (n = 3, except for pre-incubation assays with Rimonabant n = 5).
c pIC50 ± SEM, obtained from either [35S]GTPcS binding (n = 3) or b-arrestin recruitment (n = 3) assays on recombinant human CB1 receptors stably expressed on CHO cell
membranes or intact cell line.
d N.A. not applicable.
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concentration-effect curves without a suppression of the maximal
response. Notably, the Schild-slopes of the short RT antagonists (6
and rimonabant) were close to unity in both [35S]GTPcS binding
(1.1 ± 0.0 for 6, 1.2 ± 0.2 for rimonabant, Table 3) and b-arrestin
recruitment assays (0.7 ± 0.2 for 6, 1.2 ± 0.3 for rimonabant,
Table 3). In contrast, for the long RT antagonist 9 the Schild-slope
derived from both assays was well above unity (Table 3).3.8. Inverse agonism of the selected CB1 antagonists
Finally, it became clear from the [35S]GTPcS binding assays that
the antagonists behaved as inverse agonists (Fig. 7A). It follows
that all antagonists caused a dose-dependent decrease in basal
[35S]GTPcS binding. The short RT antagonist 6 was 21-fold less
potent as an inverse agonist than short RT rimonabant, while the
latter was actually equally potent to the long RT antagonist 9
(Table 3). Furthermore, we decided to investigate the presence ofinverse agonism in the b-arrestin recruitment assay. After adjust-
ing the standard protocol (i.e. extending the incubation time from
90 min to 6 h) inverse agonism was observed for all antagonists
(Fig. 7B and Table 3), as in the [35S]GTPcS binding assays.
Rimonabant was the least potent inverse agonist in the b-arrestin
recruitment assay (IC50 = 627 nM), while the short RT and long
RT antagonist had a similar potency (6: IC50 = 179 nM and 9:
IC50 = 165 nM, respectively). Overall, the inverse agonistic poten-
cies in b-arrestin recruitment assays were significantly lower than
those obtained in the [35S]GTPcS binding assays.4. Discussion
4.1. Ligand optimization based on structure-kinetics relationships
(SKR)
Receptor binding kinetics is increasingly being recognized as
an important parameter to understand a drug’s mechanism of
Fig. 5. CP55940-stimulated [35S]GTPcS binding to recombinant hCB1 receptors stably expressed on CHO cell membranes (30 C) in the absence or presence of long-
residence-time antagonist 9 (A and B), short-residence-time antagonist 6 (C and D) and reference antagonist rimonabant (E and F). Antagonist 9 (A), 6 (C) or rimonabant (E)
were either incubated for 60 min prior to the challenge with the hCB1 receptor agonist CP55940 or coincubated with CP55940 (antagonist 9, B, antagonist 6, D or rimonabant,
F). The agonist curves were generated in the presence of increasing concentrations of antagonist, namely 10-, 30-, 100-fold their respective Ki values. The shift in agonist EC50
was determined to perform the Schild analyses. A two-way ANOVA with Tukey’s post-test was applied for the comparison of Emax by agonist control, ****p < 0.0001, ns for not
significant. Data were normalized according to the maximal response (100%) produced by CP55940. Combined graphs are shown from three experiments performed in
duplicate (see Table 3 for pA2 and the Schild-slope values).
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we focused on the substitutions at the thiophene’s 3-position (R
group) in a series of rimonabant related antagonists (Table 1).
Applying equilibrium and kinetic radioligand binding assays, we
assayed the binding interactions of nine of such hCB1 receptor
antagonists together with the reference compound rimonabant.
As a result, diverse affinity and KRI values were determined and
both long and short RT antagonists were identified. Interestingly,
the recent hCB1 receptor crystal structures indicate that the
aliphatic R-substitutions fit in the lipophilic ‘‘long and narrow
channel” of the hCB1 receptor [27,39]. Apparently, targeting this
channel with diversified chemical fragments is highly relevant
for the improvement of binding interactions at the hCB1 receptor.
Specifically from antagonists 6 (RT = 19 min) and 9 (RT = 2222
min) it seems that a longer (6- vs. 5-atom) tail with less polarity
contributes significantly to slow receptor dissociation kinetics and
better affinity (1.4 nM of 9 vs. 14 nM of 6). Interestingly, the
>100-fold gain in residence time is not fully reflected in the
increase in affinity. This may in part be due to the entropic cost
of the aliphatic chain when it has to adapt to the steric require-
ments of the hydrophobic channel of the binding site, resulting
in a slower association rate [40]. Taken together, this limited
SKR study proves that kinetic profiles should and can be taken
into account during the lead optimization process in drug
discovery.4.2. The computational insights of the binding modes
Using the crystal structure of the hCB1-AM6538 complex (PDB:
5TGZ), [27] we performedWaterMap calculations to try and under-
stand the differences in residence times observed for the hCB1
receptor antagonists studied, with the hypothesis that unfavorable
hydration might provide an explanation [34,35,41,42]. We focused
on antagonist 9 and 6, and in particular the substitutions at the
thiophene’s 3-position (R-group) as this was the only structural
difference (Fig. 4). When the antagonist with the shorter and more
hydrophilic side chain (6, –SO2CH2CH2CH2OH, short RT) was
docked into the apo Watermap, it was able to displace water mole-
cules found in positionsW16 andW72; while unstable water mole-
cule W11 was still around its side chain (Fig. 4C). We propose that
the interaction with T197333 forces 6 in an orientation where its
sulfonyl further stabilized water molecules found in position
W11. By contrast, antagonist 9 was able to displace all these water
molecules (W11, W16 and W72) with its longer and more
hydrophobic side chain, a process which might raise the energy
of the transition state for dissociation (Fig. 4B). We postulate that
this destabilization of the transition state may contribute to the
prolonged RT observed with this compound. In contrast, rimona-
bant cannot displace those unhappy water similar to antagonist
6, due to its lack of the linear side chain reaching those energeti-
cally unfavorable or unhappy waters (Fig. 4A).
Fig. 6. CP55940-stimulated b-arrestin recruitment to recombinant hCB1 receptors stably expressed on CHO cells (37 C and 5% CO2) in the absence or presence of long-
residence-time antagonist 9 (A and B), short-residence-time antagonist 6 (C and D) and reference antagonist rimonabant (E and F). Antagonist 9 (A), 6 (C) or rimonabant (E)
were either incubated for 60 min prior to the challenge of the hCB1 receptor agonist CP55940 or were coincubated with CP55940 (antagonist 9, B, antagonist 6, D or
rimonabant, F). The agonist curves were generated in the presence of increasing concentrations of antagonist, namely 10-, 30-, 100-fold their respective Ki values. The shift in
agonist EC50 was determined to perform the Schild analyses. A two-way ANOVA with Tukey’s post-test was applied for the comparison of Emax by agonist control, ****p <
0.0001, ns for not significant. Data were normalized according to the maximal response (100%) produced by CP55940. Combined graphs are shown from at least three
experiments performed in duplicate (n = 3, except for pre-incubation assays with Rimonabant n = 5). (See Table 3 for pA2 and the Schild-slope values.).
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A so-called dual-point competition association assay for hCB1
receptor was applied for the ‘‘kinetic screening campaign” to
increase throughput in comparison to the traditional competition
association experiments as shown before [30]. A good correlation
between the antagonists’ KRI values and dissociation rate con-
stants (koff, k4) corroborated the robustness of this assay
(Fig. 2A). In contrast, no significant correlations were found
between the kinetic binding parameters, kon (k3) or koff (k4), and
affinity values of these antagonists (Fig. 2C, D). Besides, the equilib-
rium Ki and kinetic KD values were significantly correlated
(Fig. 2B). Noteworthy, the extraordinary long RT antagonist 9
(Fig. 3, highlighted in red color) was observed as a significant ‘‘out-
lier” in the correlation plots involving the affinity values obtained
from equilibrium assays (Fig. 2B, D). This clearly indicates that
equilibrium was not reached for this antagonist during the radioli-
gand displacement assay where a relatively short incubation time
is used. In general, equilibrium affinities of long RT antagonists
might often be underestimated and this potentially results in
ignoring such interesting compounds for further evaluation.
Subsequently, we designed a ‘‘two-step incubation” experiment
for further investigation of the affinity-shift of short and long RT
antagonists. The displacement curve of the long RT antagonists 9
was shifted leftward about 10-fold, compared to a standard affinity
determination, which was then similar to its calculated kinetic KD
(Tables 1 and 2). In contrast, the affinity of short RT antagonists (6
and rimonabant) determined in the ‘‘two-step incubation” andstandard experiments showed no such shift (Table 2). These results
once more indicate that during a longer period of incubation in the
absence of a competing ligand a larger fraction of antagonist 9
forms a tight and slowly dissociating ligand-receptor complex.
During preincubation the antagonist 9 enjoys a binding ‘‘mono-
poly” to hCB1 receptors and the occupied hCB1 receptors are
pseudo-irreversibly blocked, as antagonist 9 (with its extremely
long RT) is unlikely to dissociate again. Such a potential two-step
(or multi-step) bimolecular binding has also been reported for
CCR5 antagonists, where a shift in the apparent affinity was also
reported after pre-incubation [43]. Moreover, the pseudo-
irreversible binding of long RT antagonist 9 was also confirmed
in ‘‘wash-out” experiments, where its binding to hCB1 receptors
was washing-resistant, while short RT antagonists 6 and
rimonabant were washed away more easily (Fig. 3D). A washing-
resistant effect has been reported more often for covalently bind-
ing ligands to various targets [44–46]. While the current study
was mostly focused on developing methodologies for investigating
whether the addition of SKR would result in a different triaging of
CB1 antagonists, we are aware that the translation to native tissues
should be made. For example, it is known that CB1 receptors are
the most highly expressed receptors in the brain, where they have
been shown to form functional heteromers with other GPCRs, such
as adenosine A2A receptors [47] and b2 adrenergic receptors [48].
Although this has yet to be investigated for CB1 receptors, a
ligand’s binding kinetics is likely to be very different on a monomer
than a (hetero)dimer as was recently shown for homodimers of
adenosine A3 receptors [49,50].
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antagonists
Diverging dissociation rate constants of antagonists have been
linked to differentiation in functional effects (i.e. surmountable vs.
insurmountable antagonism) and concomitant physiological rele-
vance, even before the concept of kinetic studieswas gaining accep-
tance [51,52]. In our studies, the differences in binding interactions
between long and short RT antagonists (9 vs. 6 and rimonabant)
prompted us to further investigate potential differences in func-
tional effects. In both [35S]GTPcS binding and b-arrestin recruitment
assays, long RT antagonist 9 generated an insurmountable effect
when preincubated before stimulation with the agonist CP55940
(Figs. 5A and 6A). Importantly, when the preincubation was
excluded, its effects became surmountable proving that
(Figs. 5B and 6B) the long RT antagonist 9 prevents the agonist
CP55940 to activate receptors by competitive pseudo-irreversible
binding to hCB1 receptors, as opposed to allosterically inhibiting
CP55940 activation [53,54]. Since the short RT antagonists (6 and
rimonabant) do not occupy hCB1 receptors for that long, CP55940
was able to activate hCB1 receptors in the presence of such antago-
nists under all experimental conditions, which resulted in sur-
mountable antagonism (Figs. 5C–F and 6C–F). Moreover, the
surmountable effect can be quantified through the competitive
Gaddum-Schild analysis [55]. Here for the short RT antagonists (6
and rimonabant) the Schild-slopes close-to-unity were obtained,
which indicated a one-to-one competition with the agonist
CP55940 while equilibrium was reached. Interestingly, the Schild-
slopes determined in the experiments of long RT antagonist 9were
above 1, i.e. the EC50 shiftswere greater than predicted by such anal-
ysis. This effect can again be explained by its pseudo-irreversible
binding to the hCB1 receptor, where equilibrium was not reached
at the chosen incubation times. Of note, in native systems (i.e. underFig. 7. Characterization of inverse agonism for long RT antagonist 9, short RT antagonis
receptors stably expressed on CHO cell membranes (A) or b-arrestin recruitment to recom
ranging from 0.1 nM to 10 mM. Data were normalized according to the maximal response
performed in duplicate in A; a representative graph is shown from one experiment perfnon-equilibrium conditions) endocannabinoid exposure is high, but
short due tometabolic degradation of the agonist [56,57]. However,
long and short RT antagonists will still differentiate under these cir-
cumstances, as an insurmountable antagonist (i.e. with long RT) can
cope with the high local contractions of the endogenous agonist,
while the short RT antagonist cannot.
Secondly, the selected long or short RT hCB1 receptor antago-
nists (9, 6 and rimonabant [58]) behaved as inverse agonists in
the standard [35S]GTPcS binding assays (Table 3, Fig. 7A). In the
b-arrestin recruitment assay inverse agonism was only observed
when the assay-kit manufacturer’s protocol was adjusted to con-
tain a longer incubation time (i.e. 6-h instead of 90 min) (Fig. 7B)
[31]. Of note, the cells tolerated this increased incubation time,
since the potency of the reference agonist CP55940 did not change
(data not shown). The inverse agonism at cannabinoid receptors
(i.e. CB1 and CB2) in the b-arrestin recruitment assay has been sel-
dom reported [59]. Importantly, although we have used a cell line
that heterologously (and abundantly) expresses CB1 receptors
which might raise the question that the level of constitutive activ-
ity is an artefact, it is known that this receptor is the highest
expressed GPCR in the brain [60,61]. Moreover, the scientific com-
munity, including pharmaceutical industry, actually prompted that
the inverse agonistic characteristic might be the cause of adverse
side effects seen with CB1 antagonists and is therefore in pursuit
of ‘neutral’ antagonists [62,63]. Noteworthy, there was no correla-
tion between inverse agonism and RTs.
Lastly, the CB1 receptor is a class A GPCR and it has been
reported that its down-stream signaling pathways involve both G
protein-coupling and b-arrestin recruitment [64]. When compar-
ing the functional results from [35S]GTPcS binding and b-arrestin
recruitment, we learned the antagonists were more potent in the
former. Recently, it was reported that hCB1 receptor activation
can trigger 3 ‘‘waves” of signaling, G protein-coupling as the first,t 6 and reference antagonist rimonabant. [35S]GTPcS binding to recombinant hCB1
binant hCB1 receptors stably expressed on CHO cells (B) with ligand concentrations
(100%) produced by CP55940. Combined graphs are shown from three experiments
ormed in duplicate in B (see Table 3 for pIC50 values).
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as the last [65]. The possible correlation between binding kinetics
and signaling effects on the CB1 receptor merits further
investigation.
In conclusion, we have evaluated the binding kinetics of nine
1-(4,5-diarylthiophene-2-carbonyl)-4-phenylpiperidine-4-carboxamide
derivatives at the hCB1 receptor, and described structure-kinetics
relationships (SKR) defined by their Kinetic Rate Index (KRI) values
and dissociation rate constants. The antagonist 9 was found to be a
pseudo-irreversible hCB1 receptor antagonist with a residence
time of 2222 min at 30 C. Moreover, the difference in receptor-
ligand interaction (i.e. long vs. short RT) was correlated with the
mode of functional antagonism (insurmountable vs. surmount-
able), as determined for both G protein-dependent and indepen-
dent signaling pathways. Following from docking studies and
WaterMap calculations, we speculate that displacement of unfa-
vorable water molecules may provide a plausible explanation for
antagonist 9’s slow dissociation, or even pseudo-irreversible bind-
ing at the hCB1 receptor. These findings could be highly valuable
for the further development of potent and safe CB1 receptor antag-
onists for metabolic disorders such as obesity.Conflict of interest
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